Cargando…
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength of Intact Bones in Adult Male Rats
We investigated the systemic effect of sclerostin monoclonal antibody (Scl-Ab) treatment on intact non-operated bones in an open osteotomy male Sprague Dawley (SD) rat model. Six-month-old male SD rats were subjected to transverse osteotomy at the right femur mid-shaft. Rats were injected subcutaneo...
Autores principales: | Suen, Pui Kit, Zhu, Tracy Y., Chow, Dick Ho Kiu, Huang, Le, Zheng, Li-Zhen, Qin, Ling |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4616053/ https://www.ncbi.nlm.nih.gov/pubmed/26494536 http://dx.doi.org/10.1038/srep15632 |
Ejemplares similares
-
Sclerostin Antibody Treatment Stimulates Bone Formation to Normalize Bone Mass in Male Down Syndrome Mice
por: Williams, Diarra K, et al.
Publicado: (2017) -
Effects of anti-sclerostin antibody and running on bone remodeling and strength
por: Toumi, H., et al.
Publicado: (2015) -
Bone Matrix Levels of Dickkopf and Sclerostin are Positively Correlated with Bone Mass and Strength in Postmenopausal Osteoporosis
por: Ueland, Thor, et al.
Publicado: (2019) -
Effects of sclerostin antibody on bone healing
por: Mihara, Atsushi, et al.
Publicado: (2021) -
Influence of Muscle Mass and Strength on Bone Mineralisation with Consideration of Sclerostin Concentration
por: Patalong-Wójcik, Martyna, et al.
Publicado: (2023)